Quarterly report pursuant to Section 13 or 15(d)

Revenues from Contracts and Significant Customers (Tables)

v3.23.3
Revenues from Contracts and Significant Customers (Tables)
9 Months Ended
Sep. 30, 2023
Revenues from Contracts and Significant Customers  
Schedule of disaggregation of total revenues

Three months ended September 30, 

Nine Months Ended September 30, 

    

2023

    

2022

    

2023

    

2022

Revenue

Qbrexza

$

5,865

$

6,265

$

18,038

$

19,752

Accutane

4,882

4,121

15,109

14,228

Amzeeq

2,336

1,161

4,904

5,892

Zilxi

681

554

1,567

1,851

Targadox

929

1,168

2,386

6,558

Exelderm

764

1,001

1,813

3,018

Ximino

(199)

1,773

567

3,775

Luxamend

21

21

Collaboration revenue

182

364

546

1,518

Revenue – related party

 

31

 

48

 

97

 

118

Other revenue

19,260

73

19,519

 

2,629

Net revenue

$

34,752

$

16,528

$

64,567

$

59,339